FDA Approves FoundationOne Liquid CDx for Breast, Ovarian, Lung Cancer Indications
October 28th 2020FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
Read More
Axillary Surgery May Not Be Required for All Women With Invasive Breast Cancer
October 27th 2020An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.
Read More
Study: Mortality Rate Higher for US Rural Residents
October 27th 2020A recent study found that the US rural mortality penalty is wide and further expanding, which applies to the rural population overall, or all racial/ethnic groups combined, and for non-Hispanic whites, non-Hispanic blacks, and Hispanics individually.
Read More
COVID-19 Pandemic Beckons the Soft Skills of Mentorship, Leadership Roles to Manage Challenges
October 27th 2020During the COVID-19 pandemic, pharmacists have been forced to face challenges to their practice that have required not only adaptation and flexibility, but also moments of empathy and vulnerability.
Read More
Mystery Monday: What Money Saving Measure Could Be Causing an Infant’s Seizures?
October 26th 2020The mother of an 8-month-old infant, LG, arrives at the pharmacy to pick up her daughter’s seizure medicine, levetiracetam (Keppra) in 100 mg per ml oral solution, with 60 mg given to LG twice daily.
Read More
Study: Coronavirus Vaccines Stir Doubts Among People Worldwide
October 26th 2020The investigators found that 72% of participants would likely take the vaccine based on data collected from the previously validated COVID-SCORE survey of a sample of more than 13,400 individuals from 19 countries that were hard-hit by the virus.
Read More
FDA Approves FoundationOne CDx Genomic Test as Companion Diagnostic for Larotrectinib
October 26th 2020The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.
Read More